Imunon reports IMNN-001 boosts anti-tumor T-cell activity in Phase 2 ovarian cancer study

IMNN•2026-11-06

Imunon said new Phase 2 OVATION 2 data showed stronger anti-tumor immune activity with IMNN-001 plus chemotherapy and supported a survival benefit in newly diagnosed advanced ovarian cancer. The findings will be presented November 7, 2026, while the pivotal Phase 3 OVATION 3 trial is enrolling patients.

Imunon reports IMNN-001 boosts anti-tumor T-cell activity in Phase 2 ovarian cancer study

1. Phase 2 findings

2. Phase 3 trial

Related News

US research roundup: Airbnb, Cloudflare, Royal Gold

Fox names Roku founder Anthony Wood to board

Amundi Physical Metals issues 62,000 secured gold-linked debt securities

iRhythm to participate in three healthcare investor conferences

Democrats plan flood of AI bills when they take control of Congress